Glancy prongay & murray llp announces the proposed class action settlement on behalf of purchasers of the publicly traded common stock of adamas pharmaceuticals, inc. - adms

Oakland, calif. , may 13, 2024 /prnewswire/ -- glancy prongay & murray llp announce that the united states district court for the northern district of california has approved the following announcement of a proposed class action settlement that would benefit purchasers of the publicly traded common stock of adamas pharmaceuticals, inc. (nasdaq: adms): summary notice of (i) pendency of class action, certification of settlement class, and proposed settlement; (ii) settlement fairness hearing; and (iii) motion for an award of attorneys' fees and reimbursement of litigation expenses to: all persons and entities who, during the period between august 8, 2017 and march 4, 2019, inclusive, purchased or otherwise acquired the publicly traded common stock of adamas pharmaceuticals, inc. ("adamas"), and were damaged thereby (the "settlement class"): 1 please read this notice carefully, your rights will be affected by a class action lawsuit pending in this court.
ADMS Ratings Summary
ADMS Quant Ranking